Cargando…

Effects of Lapatinib on HER2-Positive and HER2-Negative Canine Mammary Carcinoma Cells Cultured In Vitro

HER2 is a prognostic and predictive marker widely used in breast cancer. Lapatinib is a tyrosine kinase inhibitor that works by blocking the phosphorylation of the receptor HER2. Its use is related to relatively good results in the treatment of women with HER2+ breast cancer. Thus, this study aimed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leis-Filho, Antonio Fernando, de Faria Lainetti, Patrícia, Emiko Kobayashi, Priscila, Fonseca-Alves, Carlos Eduardo, Laufer-Amorim, Renée
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235449/ https://www.ncbi.nlm.nih.gov/pubmed/34204236 http://dx.doi.org/10.3390/pharmaceutics13060897

Ejemplares similares

Establishment and Characterization of Canine Mammary Gland Carcinoma Cell Lines With Vasculogenic Mimicry Ability in vitro and in vivo
por: de Faria Lainetti, Patrícia, et al.
Publicado: (2020)

Investigation of the Prognostic Significance of Vasculogenic Mimicry and Its Inhibition by Sorafenib in Canine Mammary Gland Tumors
por: Prado, Maria Carolina Mangini, et al.
Publicado: (2019)

E-Cadherin Downregulation is Mediated by Promoter Methylation in Canine Prostate Cancer
por: Fonseca-Alves, Carlos Eduardo, et al.
Publicado: (2019)

Proteomics Approach of Rapamycin Anti-Tumoral Effect on Primary and Metastatic Canine Mammary Tumor Cells In Vitro
por: Lainetti, Patrícia F., et al.
Publicado: (2021)

A Comparative in Silico Analysis of CD24’s Prognostic Value in Human and Canine Prostate Cancer
por: Leis-Filho, Antonio Fernando, et al.
Publicado: (2021)

Firocoxib as a Potential Neoadjuvant Treatment in Canine Patients with Triple-Negative Mammary Gland Tumors
por: Brandi, Andressa, et al.
Publicado: (2022)

Deregulation of VEGFR-2 and PDGFR Expression and Microvascular Density in a Triple-Negative Model of Canine Malignant Mammary Tumors with Lymph Node or Lung Metastasis
por: dos Anjos, Denner Santos, et al.
Publicado: (2019)

Mechanisms of Resistance to Chemotherapy in Breast Cancer and Possible Targets in Drug Delivery Systems
por: Lainetti, Patrícia de Faria, et al.
Publicado: (2020)

Morphological and Molecular Characterization of Proliferative Inflammatory Atrophy in Canine Prostatic Samples
por: de Godoy Fernandes, Giovana, et al.
Publicado: (2021)

Transcriptome of Two Canine Prostate Cancer Cells Treated With Toceranib Phosphate Reveals Distinct Antitumor Profiles Associated With the PDGFR Pathway
por: Kobayashi, Priscila E., et al.
Publicado: (2020)

Characterization of Collagen Fibers (I, III, IV) and Elastin of Normal and Neoplastic Canine Prostatic Tissues
por: Calderón, Luis Gabriel Rivera, et al.
Publicado: (2019)

Investigation of c-KIT and Ki67 expression in normal, preneoplastic and neoplastic canine prostate
por: Fonseca-Alves, Carlos Eduardo, et al.
Publicado: (2017)

HER2 Overexpression and Cytogenetical Patterns in Canine Mammary Carcinomas
por: Muscatello, L. V., et al.
Publicado: (2022)

Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer
por: Han, Sae-Won, et al.
Publicado: (2012)

Structural investigations on mechanism of lapatinib resistance caused by HER-2 mutants
por: Verma, Sharad, et al.
Publicado: (2018)

Evaluation of ATM protein expression in canine mammary tumors
por: Raposo, Talita MM, et al.
Publicado: (2013)

Predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab
por: Duchnowska, Renata, et al.
Publicado: (2017)

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer
por: Collins, Denis M., et al.
Publicado: (2019)

Evaluation of c-KIT protein expression in canine mammary tumors
por: Salvador, Rosana CL, et al.
Publicado: (2013)

A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer
por: Cristofanilli, Massimo, et al.
Publicado: (2012)

Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ
por: Estévez, Laura G, et al.
Publicado: (2014)

Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma
por: De Silva, Nadeera, et al.
Publicado: (2015)

Metastatic, Her-2 Amplified Lacrimal Gland Carcinoma with Response to Lapatinib Treatment
por: Dennie, Trevor
Publicado: (2015)

Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers -- role of estrogen receptor and HER2 reactivation
por: Wang, Yen-Chao, et al.
Publicado: (2011)

Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer
por: Leung, Wing-yin, et al.
Publicado: (2015)

A Review on Canine and Feline Prostate Pathology
por: Palmieri, Chiara, et al.
Publicado: (2022)

Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients
por: Duchnowska, Renata, et al.
Publicado: (2015)

Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
por: Cheong, E. Von, et al.
Publicado: (2021)

Lapatinib dysregulates HER2 signaling and impairs the viability of human uveal melanoma cells
por: Shu, Wenying, et al.
Publicado: (2023)

Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2
por: Kim, Hwang-Phill, et al.
Publicado: (2009)

Circulating fatty acid synthase: an exploratory biomarker to predict efficacy of the dual HER1/HER2 tyrosine kinase inhibitor lapatinib
por: Oliveras-Ferraros, Cristina, et al.
Publicado: (2011)

An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models
por: Xia, Wenle, et al.
Publicado: (2013)

Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells
por: Ye, Min, et al.
Publicado: (2021)

Establishment and characterization of a HER2-enriched canine mammary cancerous myoepithelial cell line
por: Chen, Aolei, et al.
Publicado: (2023)

Protective Effect of HER2 Gene Polymorphism rs24537331 in the Outcome of Canine Mammary Tumors
por: Canadas-Sousa, Ana, et al.
Publicado: (2023)

Immunohistochemical panel to characterize canine prostate carcinomas according to aberrant p63 expression
por: Fonseca-Alves, Carlos Eduardo, et al.
Publicado: (2018)

Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor
por: Spector, Neil L., et al.
Publicado: (2015)

Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients
por: Kim, S T, et al.
Publicado: (2018)

Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1
por: Nonagase, Yoshikane, et al.
Publicado: (2016)

BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy
por: Kim, Sung-Bae, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_08h3pddll535igl7ocqorfv40o